Verdict: Side-by-side breakdown using the Bull Rankings model. DHR scored 39.0, RMD scored 75.9 — RMD leads.
Compare another set
DHR
Danaher Corporation
Diagnostics & Research · Quality-Growth
39
$219.81 · $154.5B
fundamentals as of
Score gap
36.9
RMD leads
RMD
ResMed Inc.
Medical Instruments & Supplies · Quality-Growth
75.9
$230.05 · $32.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestRMD22.1x
Fastest growthRMD+9.9%
Strongest balance sheetRMD0.13
Highest qualityRMD90 / 100
Largest discount to fair valueRMD-7%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
DHR
stronger →← stronger
RMD
61
Qualityreturns · margins · balance sheet
90
48
Growthrevenue & earnings expansion
72
20
Valuevaluation vs sector peers
68
RMD is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
DHR
RMD
$5.5bB+
FCF
$1.6bC+
+2.9%C
Rev
+9.9%B
0.53B
D/E
0.13B+
39.2xC+
P/E
22.1xB+
1.30B
PEG
1.32B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
DHR
RMD
63% above
Price vs fair valuelower is cheaper
7% below
~15%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~5%/yr
-38%
1-yr DCF upside
0%
-39%
5-yr DCF upside
+8%
-40%
10-yr DCF upside
+21%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DHR
Why this score
Raising its dividend
RMD
Why this score
Raising its dividend
Durable high returns
The companies
DHRDanaher Corporation
Diagnostics & Research · $219.81 · beta 0.80
Why now
Diagnostics & Research · market cap $154.5b. 9% off the 52-week high of $242.80. 22 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $241.00 (implying +10% upside).
Moat
Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 137% of net income — earnings translate cleanly into cash. $154.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 8% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
RMDResMed Inc.
Medical Instruments & Supplies · $230.05 · beta 0.75
Why now
Medical Instruments & Supplies · market cap $32.4b. 17% off the 52-week high of $277.67. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $250.22 (implying +9% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 108% of net income — earnings translate cleanly into cash.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where DHR and RMD diverge
On the headline score the gap is 36.9 points in favor of RMD. The widest single difference is Value, where RMD leads by 47.2 points.
ValueDHR 20.4 · RMD 67.6RMD +47.2
QualityDHR 61.0 · RMD 90.2RMD +29.2
GrowthDHR 47.8 · RMD 71.8RMD +24.0
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is RMD or DHR the better stock?
RMD scores higher: RMD 75.9, DHR 39.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do RMD and DHR differ most?
The widest gap is value, where RMD leads by 47 points on the 0–100 pillar scale. RMD leads all three pillars, so the gap is broad rather than a single-measure difference.
How are RMD and DHR scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.